Efficacy of newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a systematic review

• Published in: The aging male Vol. 22; no. 1; pp. 1 - 11
• Main Authors: MacDonald, Roderick, Brasure, Michelle, Dahm, Philipp, Olson, Carin M., Nelson, Victoria A., Fink, Howard A., Risk, Michael C., Rwabasonga, Bruce, Wilt, Timothy J.
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 02.01.2019; Taylor & Francis Ltd
• Subjects: 5-alpha reductase inhibitor; Adrenergic alpha-1 Receptor Antagonists - administration & dosage; Adrenergic alpha-1 Receptor Antagonists - adverse effects; Adrenergic beta-3 Receptor Agonists - administration & dosage; Adrenergic beta-3 Receptor Agonists - adverse effects; alpha blockers; anticholinergic: systematic review; benign prostatic hyperplasia; Bibliographic data bases; Cholinergic Antagonists - administration & dosage; Cholinergic Antagonists - adverse effects; Drug Therapy, Combination; Drugs; Evidence-based medicine; FDA approval; Humans; Hyperplasia; Lower urinary tract symptoms; Lower Urinary Tract Symptoms - drug therapy; Male; Mens health; Older people; Phosphodiesterase 5 Inhibitors - administration & dosage; Phosphodiesterase 5 Inhibitors - adverse effects; Prostate; Prostatic Hyperplasia - complications; Quality of Life; Randomized Controlled Trials as Topic; randomized trials; Systematic review; Urinary tract diseases; Urogenital system; 5-alpha reductase inhibitor; anticholinergic: systematic review; randomized trials; Lower urinary tract symptoms; alpha blockers; benign prostatic hyperplasia

We conducted a systematic review to evaluate the efficacy and adverse effects of newer drugs used to treat lower urinary tract symptoms (LUTS). The drugs were either Food and Drug Administration (FDA) approved for benign prostatic hyperplasia (BPH) or not FDA approved for BPH but have been evaluated...